MedTrace Logo

Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors

NCT07589205 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 493

Last updated 2026-05-15

No results posted yet for this study

Summary

This is a phase 1 multi-center, open-label study evaluating IBI3028 Treatment in participants with locally advanced, unresectable, or metastatic solid tumors

Conditions

Interventions

DRUG

Drug: IBI3028

Recombinant anti-EGFR（Epidermal growth factor receptor） and c-Met antibodies-dual-payload conjugate for injection

Sponsors & Collaborators

  • Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-31
Primary Completion
2027-06-30
Completion
2028-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07589205 on ClinicalTrials.gov